Literature DB >> 2245170

Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study.

M Danova1, A Riccardi, G Ucci, R Luoni, M Giordano, G Mazzini.   

Abstract

Using bivariate flow cytofluorometry, we have determined the nuclear DNA distribution and the expression of the p21 protein (coded by the Ha-ras oncogene) in the bone marrow (BM) cells of five solid tumour patients having histologically normal BM and in those of 57 patients with plasma cell dyscrasia (28 with monoclonal gammopathies of undertermined significance, MGUS, and 29 with multiple myeloma, MM). All normal and MGUS and 21/29 (72.4%) MM BM had diploid modal DNA content and 8/29 (27.6%) MM BM had both diploid and hyperdiploid cell populations. In normal and MGUS BM, the level of the p21 oncoprotein was low and uniform in all G0/G1, S and G2 cells (median fluorescence values in arbitrary units were 6.1 and 7.5, respectively). The level of p21 was increased both in different aliquots of G0/G1 cells and in the S and G2 cells in diploid MM (median value for G0/G1 cells was 20), and especially in MM with hyperdiploid clones (median value for hyperdiploid cells was 40.5, P less than 0.005 with respect to normal and MGUS BM and less than 0.005 with respect to diploid MM BM). The p21 expression was greater in patients with advanced (stage III) than in earlier MM (stages I + II) (P less than 0.005), and it was directly related to the BMPC infiltration (r = 0.7; P less than 0.005). Since p21 expression is greater in MM than in both normal and MGUS BM, Ha-ras could be involved in the malignant plasma cell transformation that distinguishes MM from MGUS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245170      PMCID: PMC1971520          DOI: 10.1038/bjc.1990.379

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene.

Authors:  D Samid; E H Chang; R M Friedman
Journal:  Biochem Biophys Res Commun       Date:  1984-02-29       Impact factor: 3.575

Review 2.  Oncogenes and cancer: the p21 ras genes.

Authors:  T Y Shih; M O Weeks
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

Review 3.  Cellular oncogenes and retroviruses.

Authors:  J M Bishop
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

4.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

5.  The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity.

Authors:  R W Sweet; S Yokoyama; T Kamata; J R Feramisco; M Rosenberg; M Gross
Journal:  Nature       Date:  1984 Sep 20-26       Impact factor: 49.962

6.  Cellular transforming genes.

Authors:  G M Cooper
Journal:  Science       Date:  1982-08-27       Impact factor: 47.728

7.  Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells.

Authors:  S L Lin; E A Garber; E Wang; L A Caliguiri; H Schellekens; A R Goldberg; I Tamm
Journal:  Mol Cell Biol       Date:  1983-09       Impact factor: 4.272

Review 8.  Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis.

Authors:  P R Greipp
Journal:  Blood Rev       Date:  1989-12       Impact factor: 8.250

9.  Reversibility of the transformed and neoplastic phenotype. IV. Effects of long-term interferon treatment of C3H/10T1/2 cells transformed by methylcholanthrene and SV40 virus.

Authors:  D Brouty-Boyé; J Wybier-Franqui; C Calvo; J Feunteun; I Gresser
Journal:  Int J Cancer       Date:  1984-07-15       Impact factor: 7.396

10.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539

View more
  4 in total

1.  Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.

Authors:  A Riccardi; M Danova; A Paccagnella; M Giordano; A Favaretto; M Panozzo; C Ghiotto; S Comis; M Fiorentino; L Chieco-Bianchi
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

2.  Histochemistry in Advanced Cytometry: From Fluorochromes to Mass Probes.

Authors:  Giuliano Mazzini; Marco Danova
Journal:  Methods Mol Biol       Date:  2023

3.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

4.  The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

Authors:  B C Millar; J B Bell; R Barfoot; M Everard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.